Archive for the ‘Diagnostics’ Category



Agilent makes investment in Lasergen

March 8th, 2016
Posted by

3d_dna

Agilent is investing $80 million in our client Lasergen, an emerging biotechnology company with innovative next-generation sequencing (NGS) technology. The two companies will collaborate on building a NGS solutions workflow for clinical applications, based on Lasergen’s Lightning Terminators™ sequencing chemistry.

This recent investment showcases the trend toward new players and innovative technology in the NGS space, particularly as the technology moves to more routine clinical use.

Lasergen’s relationship with Agilent is another example of how Popper and Company helps companies create transformative business partnerships.

 

Save

Tags: , , ,
Posted in Diagnostics, Our Views | Comments Off on Agilent makes investment in Lasergen





Diversigen, Baylor Miraca Form Partnership

February 26th, 2016
Posted by

 

clinical_studies

The recent partnership between Diversigen and Baylor Miraca Genetics highlights the importance of both human genetics and the microbiome in drug development and ultimately in clinical decision making.

We are in the early days of understanding the scope of the impact of the microbiome but we already know of powerful associations in diseases as diverse as inflammatory bowel disease, diabetes and cancer.

We are excited about this partnership as it leverages real technical and interpretive expertise across across a broad array of genomes relevant to human health.

Read more about their partnership.

Tags: , , , ,
Posted in biomedical research, Diagnostics | Comments Off on Diversigen, Baylor Miraca Form Partnership





When Shooting at the Moon, Take Careful Aim Before Firing

February 23rd, 2016
Posted by

During his final State of the Union address, President Obama announced he is charging Vice President Biden with leading a new “moonshot” program to accelerate the pace of improvements in cancer care. While the goal is certainly laudable, I share the “sense of déjà vu” that was eloquently expressed by Vinay Prasad in his recent editorial1 in which he recounts the limited progress seen in the Nixon-era War on Cancer, and even more recently in the G.W. Bush era, when then-NCI Director Andrew Van Eschenbach testified that we could rid the world of cancer by 2010 for just $600 million per year.
Read the rest of this entry »

Posted in biomedical research, Diagnostics, Digital health, Our Views | Comments Off on When Shooting at the Moon, Take Careful Aim Before Firing





Congratulations to Withings!

January 22nd, 2016
Posted by

Congratulations to our client, Withings, for being honored with the 2016 CES Innovation Awards in two categories, as well as being given the ‘Best of CES’ Awards from many major publications. Withings hit the press jackpot with their two latest innovations:
Read the rest of this entry »

Tags: , , , , , ,
Posted in Diagnostics, Digital health, Our News | Comments Off on Congratulations to Withings!





Single Cell Biology: A Step Toward Precision Diagnostics

January 21st, 2016
Posted by

The past several years have seen a dramatic increase in the ability to isolate and characterize single cells – leading to advances in diagnostics, drug discovery, stem cell biology, cancer, and many other areas of biomedical research.

These advances have arisen thanks to growing capabilities in various single cell “omics” technologies – which have enabled RNA and DNA sequencing on a genome-wide scale (the interrogation of proteins, metabolites, and many other types of molecules that provide information about cellular growth, differentiation, and the underlying molecular basis of disease).

And why has single cell technology become so attractive within the biomedical research community? Because most studies are currently hampered by sample heterogeneity.

Read the rest of this entry »

Tags: , , , , ,
Posted in biomedical research, Diagnostics, Our Views | 1 Comment »





What Good Is Digital Health If Patients Won’t Use It?

January 5th, 2015
Posted by

Our team often talks about the promise of digital health and how it can help empower patients over their own health. From Fitbits to ECG-equipped smartphones to remote telehealth clinics, this new technology is touted as a revolutionary change in medicine.

But what if a patient doesn’t use the technology? What if, like the legendary January gym membership, the wearable’s shine wears off after about three months? A recent Juniper Research study in the United Kingdom predicted that fitness monitoring wearables would dominate the wearable market until 2018—but only for fitness applications. An article in Forbes was itself dominated by quotes from various experts who claimed that digital health would not hold a patient’s (or doctor’s) interest until the technology could demonstrate the value of counting steps, breaths or pushups. And yet another study showed that patients thought digital fitness monitors could help improve their health, but they didn’t want to pay for the technology.

Read the rest of this entry »

Posted in Diagnostics, Digital health, Our Views | Comments Off on What Good Is Digital Health If Patients Won’t Use It?